IP Library › Patent Application 10595709
Patent Application
App. No. 10/595,709

MYO-INOSITOL HEXAPHOSPHATE FOR TOPICAL USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/595,709
Abstract

The invention relates to a composition that includes myo-inositol hexaphosphate applied by topical administration for utilisation in the treatment or prevention of a disease associated with the development of heterogeneous nucleants in a soft tissue. Said composition can be used for manufacturing a drug for the treatment of a disease associated with the development of heterogeneous nucleants in a soft tissue

Claims (13)

1 . Composition including myo-inositol hexaphosphate in a form adapted to topical administration for use in the treatment or prevention of a disease associated with the development of heterogeneous nucleants in a soft tissue.

2 . Composition including myo-inositol hexaphosphate according to claim 1 for use in the treatment of a disease associated with the development of calcifications in a soft tissue.

3 . Composition including myo-inositol hexaphosphate according to any of the preceding claims, in which said soft tissue is a subepithelial tissue.

4 . Composition including myo-inositol hexaphosphate according to claim 1 and/or 2 , in which said soft tissue is a renal tissue.

5 . Composition including myo-inositol hexaphosphate according to claim 1 and/or 2 , in which said soft tissue is a pulmonary tissue.

6 . Composition including myo-inositol hexaphosphate according to claim 1 and/or 2 , in which said soft tissue is a cerebral tissue.

7 . Composition including myo-inositol hexaphosphate according to claim 1 and/or 2 , in which said soft tissue is the wall of a blood vessel.

8 . Use of a composition according to any of claims 1 to 5 for the manufacture of a medicament for the treatment of a disease associated with the development of heterogeneous nucleants in a soft tissue.

9 . Use according to claim 8 , in which said disease consists on a subepithelial dystrophic calcification.

10 . Use according to claim 8 , in which said disease consists on an arterial calcification.

11 . Use according to claim 8 , in which said disease consists on a renal calcification.

12 . Use according to claim 8 , in which said disease consists on a cerebral calcification.

13 . Use according to claim 8 , in which said disease consists on a pulmonary calcification.

Assignments (2)
CHANGE OF NAME Recorded Jun 5, 2019
From: LABORATORIS SANIFIT S.L.
To: SANIFIT THERAPEUTICS S.A.
Reel/Frame 051483/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2006
From: GRASES FREIXEDAS, FELICIA; PERELLO BESTARD, JOAN; ISERN AMENGUAL, BERNAT; PRIETO ALMIRALL, RAFAEL; COSTA BAUZA, ANTONIA
To: LABORATORIOS SANIFIT, S.L.
Reel/Frame 017688/0786 →